Memorial Sloan Kettering Cancer Center
mskcc.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,942
Active
706
Phase 3
72
Total enrollment
329,409
Pipeline matrix
Showing 40 of 421 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Vancomycin and Gentamicin | — | — | — | — | — | 1 | |
| Revaree Plus | — | — | — | — | — | 1 | |
| Nicotine Replacement Therapy | — | — | — | — | — | 1 | |
| Nicotine Lozenge | — | — | — | — | — | 1 | |
| cyclophosphamide | — | 63 | |||||
| Gemcitabine | — | — | 26 | ||||
| rituximab | — | 28 | |||||
| Fludarabine | — | — | 16 | ||||
| docetaxel | — | — | — | 18 | |||
| Chemoradiation | — | — | — | — | 3 | ||
| N-Acetylcysteine | — | — | — | 3 | |||
| Ibrutinib | — | — | 10 | ||||
| methylprednisolone | — | — | — | — | 5 | ||
| Radium-223 | — | — | — | — | 2 | ||
| Methadone | — | — | — | — | 2 | ||
| CAR-T | — | — | — | — | — | 1 | |
| Bupivacaine | — | — | — | — | — | 1 | |
| Alvimopan | — | — | — | — | — | 1 | |
| antibiotic prophylaxis | — | — | — | — | — | 1 | |
| Hemostatic Agent | — | — | — | — | — | 1 | |
| Nadofaragene Firadenovec | — | — | — | — | — | 1 | |
| opioid | — | — | — | — | — | 1 | |
| Amiodarone | — | — | — | — | — | 1 | |
| Local anesthesia | — | — | — | — | — | 1 | |
| Docetaxel 75 mg/m2 | — | — | — | — | — | 1 | |
| Docetaxel 60 mg/m2 | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | 35 | ||||
| Nivolumab | — | — | 29 | ||||
| carboplatin | — | — | 36 | ||||
| cisplatin | — | — | 62 | ||||
| dexamethasone | — | — | — | — | 29 | ||
| Venetoclax | — | — | — | — | 8 | ||
| etoposide | — | — | 32 | ||||
| Doxorubicin | — | — | — | — | 9 | ||
| Ruxolitinib | — | — | — | — | 8 | ||
| ifosfamide | — | — | — | 24 | |||
| Lenalidomide | — | — | — | — | 20 | ||
| Abemaciclib | — | — | — | — | 7 | ||
| Ivonescimab | — | — | — | — | 6 | ||
| Obinutuzumab | — | — | — | — | 6 |
381 more active programs hidden
Next readouts
- 2019-01-11
- 2022-12-19
- 2023-02-06
- 2024-07-02
- 2024-09-09
- 2024-10-11
- 2025-05-21
- 2025-05-29
- 2025-06-15
- 2025-07-07
Top conditions
- Breast Cancer210
- Prostate Cancer129
- Lung Cancer98
- Lymphoma91
- Leukemia85
- Ovarian Cancer75
- Colorectal Cancer57
- Sarcoma55
Frequently asked questions about Memorial Sloan Kettering Cancer Center
- How many clinical trials does Memorial Sloan Kettering Cancer Center have on ClinicalTrials.gov?
- Memorial Sloan Kettering Cancer Center is listed as the lead sponsor on 1,942 clinical trials in ClinicalTrials.gov, 706 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Memorial Sloan Kettering Cancer Center's trials are in Phase 3?
- 72 of Memorial Sloan Kettering Cancer Center's trials are in Phase 3, spread across 421 active drug programs.
- What therapeutic areas does Memorial Sloan Kettering Cancer Center focus on?
- Memorial Sloan Kettering Cancer Center's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Prostate Cancer, Lung Cancer, Lymphoma, Leukemia.
- When are Memorial Sloan Kettering Cancer Center's next clinical trial readouts?
- Memorial Sloan Kettering Cancer Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma”, expected around 2019-01-11.